- Home
- NVCR vs CERT Comparison
NVCR vs CERT Comparison
Compare NVCR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | CERT |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVCR | CERT |
|---|---|---|
| Price | $12.11 | $9.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $28.42 | $14.50 |
| AVG Volume (30 Days) | 1.9M | ★ 2.8M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $642,269,000.00 | $415,551,000.00 |
| Revenue This Year | $9.75 | $10.82 |
| Revenue Next Year | $5.62 | $6.77 |
| P/E Ratio | ★ N/A | $136.31 |
| Revenue Growth | 11.17 | ★ 11.47 |
| 52 Week Low | $10.70 | $8.03 |
| 52 Week High | $34.13 | $15.69 |
Technical Indicators
Market Signals| Indicator | NVCR | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 44.31 |
| Support Level | $10.79 | $8.75 |
| Resistance Level | $11.86 | $9.72 |
| Average True Range (ATR) | 0.59 | 0.37 |
| MACD | 0.06 | 0.21 |
| Stochastic Oscillator | 65.00 | 67.85 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.